August 17, 2021
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
May 20, 2021
Aurinia to Present Supportive Aurora 2 Continuation Study Interim Analysis Demonstrating Long-term Safety & Efficacy of Lupkynis™ (Volclosporin) in Subjects with Lupus Nephritis
April 15, 2021
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
No current content.